Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3821 - A Phase I/Ib Study of Concurrent Intravenous (IV) and Intrathecal (IT) Nivolumab (Nivo) for Melanoma Patients (pts) with Leptomeningeal Disease (LMD)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Isabella Glitza

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

I.C. Glitza, M.L. Rohlfs, M. Iqbal, J. Richard, E. Burton, S. Duncan, C. Brown, J. Anderson, P. Hwu, W. Hwu, M. Wong, C. Yee, S. Patel, S. Woodman, R. Amaria, A. Diab, H. Tawbi, M. Davies

Author affiliations

  • Melanoma Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
More

Resources

Abstract 3821

Background

Although advances in treatment with immune checkpoint inhibitors (CPI) have greatly improved the survival for pts with metastatic melanoma (MM), many still progress and ultimately die from this disease. Metastases to the Central Nervous System (CNS) are one of the most common and devastating complications of MM, occurring in up to 60% of pts and those with LMD have the worst prognosis (overall survival only weeks) and limited treatment options. Our program has demonstrated that IT administration of interleukin-2 (IL2) induces durable disease control and prolonged survival in pts with LMD, with 1, 2, 5- year survival rates of 36%, 26%, and 13% respectively. Given the favorable clinical activity and safety compared to systemic IL2 and supported by pre-clinical data, we hypothesize that IT administration of nivo is safe and will induce CNS immune responses in pts with LMD.

Trial design

This single center Phase I/Ib trial (NCT03025256) will treat MM LMD pts with concurrent IT (via Ommaya) and IV nivo. The initial dose escalation phase (up to 18pts) will determine the safety and recommended dose (primary objective) followed by an expansion cohort (12 pts) at the recommended dose to assess overall survival (secondary objective). Cycle 1 will consist of IT nivo only at a starting flat dose of 5mg. In subsequent cycles, IT nivo will be followed the next day by IV nivo 240mg Q2W. Pts will be hospitalized overnight for the IT dosing and monitored for neurotoxicity, including signs of elevated intracranial pressure. We will use the Bayesian mTPI method to determine the recommended dose. Pts must have radiographic and/or CSF cytopathologic (CSF) confirmed LMD. Prior therapy with systemic CPI and steroid use (≤ 4 mg / 24 hrs of dexamethasone or equivalent) to control CNS symptoms is allowed. Exploratory objectives include the evaluation of immunological effects of this treatment on immune cells in the CSF versus peripheral blood and non-LMD tumors. This is the first in human study for LMD pts to receive CPI via IT and systemic administration concurrently. This approach has great potential to be a safe and more efficacious therapy in MM patients with LMD for which there is an urgent unmet need.

Clinical trial identification

NCT03025256.

Legal entity responsible for the study

University of Texas MD Anderson Cancer Center.

Funding

Bristol-Myers Squibb.

Editorial Acknowledgement

Disclosure

I.C. Glitza: Research trial funding: BMS. W-J. Hwu: Research grant: BMS. M. Wong: Advisory board: EMD-Serono, Pfizer, Merck. R. Amaria: Research trial funding: BMS. H. Tawbi: Consulting/participated advisory boards: Merck, BMS, Genentech, Novartis; Research funding (institution): Merck, GSK, BMS, Genentech, Celgene. M. Davies: Advisory board, BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.